What Is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials

Journal of Rheumatology

Volumn 34, Issue SUPPL. 79, 2007, Pages 15-20

  Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

B cell; Clinical trials; Rheumatoid arthritis; T cell; Targeted therapies

Indexed keywords

ABATACEPT; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RITUXIMAB; ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; B LYMPHOCYTE; CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION REACTION; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DYSPNEA; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; T LYMPHOCYTE; URTICARIA; WHEEZING; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; T-LYMPHOCYTES;

EID: 34447527513     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. St. Clair EW, van der Heijde DMFM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
2. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
4. Combe B. Switching between anti-TNF-α agents: what is the evidence? Joint Bone Spine 2004;71:169-71.
5. Finckh A, Simard JF, Gabay C, Guerne PA, for the SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
6. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology Oxford 2006;45:1121-24.
7. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
8. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-35.
9. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:856-76.
10. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
11. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
12. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
13. Schiff M, Keiserman M, Codding C, et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial [abstract]. Arthritis Rheum 2006;54 Suppl:L43.
14. Orencia package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2005.
15. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
16. Moreland LW, Combe B, Steinfeld SD, et al. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies [abstract OP0183]. Ann Rheum Dis 2006;65 Suppl 2:110.
17. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
18. Simon TA, Smitten AL, Boodhoo T, et al. Observed and expected malignancies in the abatacept clinical development program: an epidemiologic assessment [abstract SAT0132]. Ann Rheum Dis 2006;65 Suppl 2:489.
19. Emery P, Fleischmann R, Filipowicz-Sosnowski A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
20. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
21. Fleischmann RM, Racewicz AJ, Schechtman J, et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: results from the Dose-ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) study [abstract]. Arthritis Rheum 2005;52 Suppl:S130.
22. Cohen S, Emery P, Greenwald M, et al. Prolonged efficacy of rituximab in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (REFLEX study) [abstract THU0220]. Ann Rheum Dis 2006;65 Suppl 2:183.
23. Kremer JM, Tony H, Tak PP, et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors [abstract FRI0133]. Ann Rheum Dis 2006;65 Suppl 2:326.
24. Keystone E, Emery P, Peterfy CG, et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study) [abstract OP0016]. Ann Rheum Dis 2006;65 Suppl 2:58.
25. Keystone E, Fleischmann R, Emery P, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors [abstract FRI0125]. Ann Rheum Dis 2006;65 Suppl 2:323.
26. van Vollenhoven RF, Cohen S, Pavelka K, et al. Response to rituximab in patients with rheumatoid arthritis is maintained by repeat therapy: results of an open-label trial [abstract SAT0197]. Ann Rheum Dis 2006;65 Suppl 2:510.
27. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50. Epub 2006 Oct 26.
28. van Vollenhoven RF, Emery P, Bingham C, et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis [abstract FRI0151]. Ann Rheum Dis 2006;65 Suppl 2:332.
29. Rituxan package insert. South San Francisco, CA: Biogen Idec and Genentech, Inc.; 2006.